Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma
Clinical trial NCT00928902 · COMPLETED
Trial details
- NCT number
- NCT00928902
- Sponsor
- University of Virginia
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 1999-11-01
- Primary completion
- 2001-04-01
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.